TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1657799
Drug: Intravenous enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous enalaprilat (0.2-1.2 mg, mean 1.0 mg) administered as bolus to 20 patients
Study: 1657799
Drug: Intravenous enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous enalaprilat (1 mg) administered as infusion over two hours to 20 patients
Study: 1657799
Drug: Intravenous enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous enalaprilat (1 mg) administered as infusion over two hours to 8 patients with systolic blood pressure between 100-109 mmHg
Study: 1657799
Drug: Intravenous enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous enalaprilat
Study: 1657799
Drug: Oral enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enalapril (2.5-10 mg/day) continued after intravenous treatment
Study: 1657799
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (thrombolytic treatment, intravenous metoprolol, intravenous nitroglycerin, intravenous furosemide)
Study: 7041943
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum (CP) immunotherapy
Study: 16083704
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg/day for 1 week)
Study: 16083704
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (1 g/day for 3 weeks)
Study: 7577895
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g textured vegetable protein (TVP)/d, containing 45 mg conjugated isoflavones
Study: 7577895
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g miso/d, containing 25 mg unconjugated isoflavones
Study: 7577895
Drug: 28 g
Normalized name: SM Syringe 28 g, 0.5cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 g TVP/d, containing 23 mg conjugated isoflavones
Study: 7577895
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g of a soyabean product with chemically extracted isoflavones (Arcon F)
Study: 7577895
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg conjugated isoflavones as 60 g TVP
Study: 7577895
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg conjugated isoflavones
Study: 7577895
Drug: 23 mg
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23 mg conjugated isoflavone-free Arcon F
Study: 31637668
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg or 250 mg daily for a 4-week cycle)
Study: 29022390
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 (LR DSM 17938) administered for 105 days, double dosage of 4×10^8 cfu for the first 15 days, followed by standard dosage of 2×10^8 cfu
Study: 26688435
Drug: Oil capsules
Normalized name: Castor Oil Capsules
DrugBank: Coffea arabica seed, roasted (DB15603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil capsules
Study: 8557138
Drug: Danazol 600
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 600 mg/d for 2 to 4 weeks (n = 15)
Study: 8557138
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot 3.75 mg for 2 months (n = 15)
Study: 6125562
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antipsychotic and antidepressant medication
Study: 30856181
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine and midazolam (KMIN)
Study: 30856181
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine and midazolam (KMO)
Study: 30856181
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (MO)
Study: 15110095
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of PhIP (7.4 ng/g)
Study: 15110095
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of PhIP (1.7 ng/g)
Study: 8056578
Drug: Azelastine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine (2 mg) + vitamin C (500 mg) + vitamin E (200 mg) + glutathione (200 mg)
Study: 3202095
Drug: Combined restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined restriction of thiamin, riboflavin, and vitamins B-6 and C with supplementation of other vitamins at twice the RDA.
Study: 3202095
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with supplementation of twice the RDA of all vitamins.
Study: 31715039
Drug: Routine intravenous
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine intravenous injection procedure
Study: 26518955
Drug: L-alanyl-glutamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alanyl-glutamine (50 g)
Study: 24617168
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg and placebo
Study: 24617168
Drug: Ginger 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger 750 mg and placebo
Study: 24617168
Drug: Ginger 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger 750 mg and Diclofenac 50 mg
Study: 17052502
Drug: Bortezomib (Velcade)
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib (Velcade) treatment
Study: 14727011
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral daily ibandronate (2.5 mg/day)
Study: 14727011
Drug: Intermittent oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent oral ibandronate (20 mg every other day for 12 doses every 3 months)
Study: 11518354
Drug: Disodium clodronate
Normalized name: clodronate disodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium clodronate (300 mg to 900 mg intravenously)
Study: 2970805
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic factor (ANF, 99‐126) infusion at 15 ng.kg‐1.min‐1 for 20 minutes
Study: 30185428
Drug: Multisystemic Therapy‐Health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic Therapy‐Health Care
Study: 30185428
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control (weekly family supportive counseling)
Study: 26637169
Drug: Competitive feedback
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Competitive feedback strategy (providing non-anonymous comparative feedback on appropriateness of antibiotic use)
Study: 22968306
Drug: Protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation (15 g·d‐1)
Study: 18781069
Drug: Calcium pre-rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium pre-rinse followed by a 228 microg/g F rinse
Study: 18781069
Drug: 912 microg/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 912 microg/g F rinse
Study: 18781069
Drug: 228 microg/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 228 microg/g F rinse
Study: 17161060
Drug: s.c. beta-EPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. beta-EPO for 3 months twice weekly, in addition to daily oral iron
Study: 17161060
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline in s.c. injections and daily oral iron
Study: 14616408
Drug: Voriconazole 3
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole 3 mg kg‐1 twice daily
Study: 14616408
Drug: Voriconazole (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (various doses)
Study: 9565125
Drug: Ketorolac tromethamine,
Normalized name: Ketorolac Tromethamine, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac tromethamine, 60 mg intravenously at the time of trocar insertion
Study: 9565125
Drug: Ibuprofen, 800
Normalized name: Ibuprofen, 800 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 800 mg orally an hour before surgery
Study: 2548964
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (50-80 mg/kg/day in three doses during meals)
Study: 2548964
Drug: Co-trimoxazole (6-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (6-10 mg trimethoprim/kg/day in two doses after meals)
Study: 7576
Drug: Propranolol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol alone (80 to 160 mg)
Study: 7576
Drug: Combined propranolol
Normalized name: propranolol and other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined propranolol (80 to 160 mg) and phenoxybenzamine (20 to 50 mg)
Study: 7576
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with hydrochlorothiazide (50-100 mg)
Study: 7576
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with hydrochlorothiazide
Study: 21673660
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide (CP) - oral metronomic dosing (50 mg/day)
Study: 21673660
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide (CP) - single intravenous dose (1,000 mg)
Study: 21673660
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide (CP) - both oral and intravenous
Study: 17507163
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg (P600)
Study: 12845210
Drug: Raltitrexed 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed 3.0 mg/m² and oxaliplatin 130 mg/m² intravenously on day 1 every 3 weeks
Study: 30132999
Drug: Neurorehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurorehabilitation therapy for 24 weeks (6 hours per week)
Study: 30132999
Drug: Neurorehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurorehabilitation therapy
Study: 27149033
Drug: Catheter ablation
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter ablation with continuation of baseline antiarrhythmic medications
Study: 27149033
Drug: Escalated antiarrhythmic
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated antiarrhythmic drug therapy (including amiodarone and mexiletine)
Study: 24119840
Drug: Daily topical
Normalized name: Clindagel 1 % Once-Daily Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily topical exit-site application of antibacterial honey plus standard exit-site care
Study: 24119840
Drug: Standard exit-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard exit-site care plus intranasal mupirocin prophylaxis (control group)
Study: 21427992
Drug: safocid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: safocid (1 g of seknidasol, 1 g of azitromycin, 150 mg of fluconasol)
Study: 16496206
Drug: Innovative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovative treatment designs
Study: 11805482
Drug: Tc-99m tetrofosmin
Normalized name: Tc-99m tetrofosmin
DrugBank: Technetium Tc-99m tetrofosmin (DB09160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tc-99m tetrofosmin myocardial SPECT exercise and resting imaging; dosage: 370 MBq (10 mCi) during exercise, 740 MBq (20 mCi) at rest; duration: imaging performed at specified intervals after injection
Study: 1657803
Drug: Itraconazole with
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole with isoconazole cream
Study: 1657803
Drug: Itraconazole with
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole with keratolytic cream
Study: 1657803
Drug: Itraconazole with
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole with placebo cream
Study: 1657803
Drug: Griseofulvin with
Normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin with isoconazole cream
Study: 1657803
Drug: Griseofulvin with
Normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin with keratolytic cream
Study: 1657803
Drug: Griseofulvin with
Normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin with placebo cream
Study: 6176320
Drug: Local nodal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local nodal radiotherapy followed by chemotherapy
Study: 6176320
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus radiotherapy to areas of bulky disease
Study: 7881703
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg methylprednisolone tablet (Medrol)
Study: 7881703
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg methylprednisolone intravenous formulation (Solu‐Medrol)
Study: 2850132
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg IV)
Study: 2850132
Drug: Enalapril (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (30 mg day‐1 for 3 months)
Study: 30383486
Drug: Cholecalciferol (D3)
Normalized name: CHOLECALCIFEROL (D3) 50MCG/DROP
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (D3) 2,000 IU daily
Study: 30383486
Drug: Cholecalciferol (D3)
Normalized name: CHOLECALCIFEROL (D3) 50MCG/DROP
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (D3) 3,000 IU daily
Study: 30383486
Drug: Ergocalciferol (D2)
Normalized name: ERGOCALCIFEROL (D2) 200MCG/ML ORAL DROPS
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergocalciferol (D2) 50,000 IU weekly
Study: 30383486
Drug: Ergocalciferol (D2)
Normalized name: ERGOCALCIFEROL (D2) 200MCG/ML ORAL DROPS
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergocalciferol (D2) 50,000 IU twice weekly
Study: 24263123
Drug: L‐NMMA in
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA in healthy control subjects (CON)
Study: 24263123
Drug: L‐NMMA in
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA in patients with CHF
Study: 8427434
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg single-dose IM injection)
Study: 8427434
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline IM injection)
Study: 2831320
Drug: Linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleic acid (4 g daily safflower seed oil)
Study: 19548448
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Simo Decoction for STC patients in control group I (62 patients)
Study: 19548448
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Simo Decoction for MC patients in control group II (62 patients)
Study: 15127082
Drug: citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: citalopram (20 mg)
Study: 15127082
Drug: escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram (10 mg)
Study: 7587035
Drug: Ceftriaxone 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 4 g once daily
Study: 7587035
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g every 12 h
Study: 2378239
Drug: alfentanil +
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil + 67% N2O + 33% O2 + droperidol 0.015 mg/kg
Study: 2378239
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (alfentanil + 67% N2O + 33% O2 + droperidol 0.015 mg/kg)
Study: 489767
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg indoprofen
Study: 17288692
Drug: Standard Current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Current Therapy (SCT)
Study: 15450616
Drug: Double infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double infusion method
Study: 9492772
Drug: Ritonavir 600
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir 600 mg twice daily (n = 543)
Study: 8288782
Drug: Acitretin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (20 to 30 mg/day for 16 weeks)
Study: 2205115
Drug: doxepin hydrochloride,
Normalized name: Doxepin Hydrochloride, 3 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxepin hydrochloride, up to 150 mg/day
Study: 2205115
Drug: inert medication
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: inert medication
Study: 198914
Drug: Stage grouping
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage grouping modification suggested by the Radiation Therapy Oncology Group
Study: 21596189
Drug: Postoperative patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative patient‐controlled epidural analgesia (PCEA) with continuous infusion of ropivacaine and fentanyl (Group I)
Study: 21596189
Drug: Postoperative patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative patient‐controlled continuous wound catheter infusion of ropivacaine (Group II)
Study: 18823218
Drug: Posaconazole oral
Normalized name: posaconazole Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole oral suspension 200 mg 3 times/day with meals or a nutritional supplement for a minimum of 7 days to achieve steady state and for a maximum of 12 weeks.
Study: 18823218
Drug: Posaconazole oral
Normalized name: posaconazole Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole oral suspension 200 mg 3 times/day
Study: 11179517
Drug: tirofiban plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: tirofiban plus heparin
Study: 8275477
Drug: ICI 182780
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 182780 (6 mg)
Study: 29340354
Drug: Four immediately
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four immediately loaded mini dental implants (MDIs)
Study: 29340354
Drug: Two standard‐sized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two standard‐sized interconnected implants (STL)
Study: 29340354
Drug: Two STL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two STL implants
Study: 26630974
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 ≥ 0.76 and 25(OH)D ≥ 50 nmol/l
Study: 26630974
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 ≥ 0.76 and 25(OH)D < 50 nmol/l
Study: 26630974
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 < 0.76 and 25(OH)D ≥ 50 nmol/l
Study: 26630974
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 < 0.76 and 25(OH)D < 50 nmol/l
Study: 24131095
Drug: Intradermal radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal radiofrequency (RF) prior to hyaluronic acid (HA) filler
Study: 11835456
Drug: Intramuscular botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular botulinum toxin type A (BT‐A) with electrical stimulation (Group A, n = 6)
Study: 11835456
Drug: Intramuscular botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular botulinum toxin type A (BT‐A) alone (Group B, n = 6)
Study: 2590625
Drug: Coal tar
Normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coal tar gel
Study: 5473608
Drug: Electrolyte solution
Normalized name: electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte solution containing both glucose and glycine
Study: 5473608
Drug: Electrolyte solution
Normalized name: electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte solution containing glucose
Study: 5473608
Drug: Electrolyte solution
Normalized name: electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte solution containing glycine
Study: 24247812
Drug: Metoprolol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol IR 50 mg four times daily
Study: 24247812
Drug: Metoprolol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol IR 100 mg twice daily
Study: 11413739
Drug: Azelastine (1.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine (1.12 mg/day) nasal spray administered twice daily
Study: 11413739
Drug: Levocabastine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine (0.4 mg/day) nasal spray administered twice daily